AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market ...

Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) program Early indication of monotherapy activity in CTLA-4 ETB (MT-8421) program through T-reg depletion; no drug-related adverse events > grade 2 Novel mechanism of action targeting CD38+ immune cells of B-cell, T-cell, and monocytic lineage representing enhanced potency in I&I without the need for conditioning therapy AUSTIN, Texas, Aug. 14, 2 ...

AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM"), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or "ETBs") for cancer and immune-mediated disease, today provided an update on its clinical-stage programs. Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, "ETBs are a potentially powerful therapeut ...

AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM"), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or "ETBs") for cancer and immune-mediated disease, today provided an update on its clinical-stage programs. MT-8421 (CTLA-4 ETB) Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, "ETBs are a potential ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...

Financial Performance - Net income attributable to common shareholders for Q1 2024 was $0.6 million, or $0.11 per basic share, a significant decrease from $10.8 million, or $2.89 per basic share, in Q1 2023[4] - Revenues for Q1 2024 were $11.1 million, down from $36.6 million in the same period of 2023, representing a decline of approximately 69.6%[4] - Total research and development expenses for Q1 2024 were $7.4 million, compared to $19.0 million in Q1 2023, reflecting a decrease of about 61%[5] - Total general and administrative expenses for Q1 2024 were $3.7 million, down from $5.8 million in Q1 2023, a reduction of approximately 36%[5] - As of March 31, 2024, cash and cash equivalents totaled $6.8 million, down from $11.5 million at the end of 2023[6] - The company expects its cash resources, including gross proceeds of approximately $9.5 million from financing, to support operations into Q4 2024[6] Clinical Developments - Clinical data presented at the 2024 AACR Annual Meeting showed promising efficacy for MT-6402 in relapsed/refractory HNSCC patients, with 2 confirmed partial responses and 4 stable diseases observed[8] - An expansion cohort for MT-6402 monotherapy in relapsed/refractory HNSCC is underway, with data expected by year-end 2024[8] - The Phase 1 dose escalation for MT-8421 is ongoing, with observations of a unique pharmacodynamic profile[8] - The company completed the second closing of the July 2023 financing in April 2024, raising approximately $9.5 million[8]

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ("ETBs"), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024. Recent Company Highlights Eric Poma, PhD., Chief Executive an ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32979 MOLECULAR TEMPLATES, INC. Delaware 94-3409596 (State or other jurisdiction of incorporation or organization) ...

EXHIBIT 99.1 Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM"), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ("ETBs"), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial resul ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32979 Molecular Templates, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...